- β-Adrenergic Signaling Impairs Antitumor CD8
β-Adrenergic Signaling Impairs Antitumor CD8
Cancer immunology research (2017-11-18)
Michael D Nissen, Erica K Sloan, Stephen R Mattarollo
PMID29146881
RESUMEN
β-Adrenergic receptor (βAR) signaling regulates many physiological processes, including immune system responses. There is growing evidence also for βAR-induced modulation of cancer growth and metastasis. In the Eμ-myc mouse model of B-cell lymphoma, we investigated the effects of chronically elevated βAR signaling on lymphoma progression and antitumor immunity, as well as the impact on cancer immunotherapy. Chronic treatment with the nonselective β-agonist isoprenaline promoted lymphoma development in a manner dependent on signaling within the hematopoietic compartment. βAR signaling significantly suppressed the proliferation, IFNγ production, and cytolytic killing capacity of antigen-specific CD8
MATERIALES
Referencia del producto
Marca
Descripción del producto
Sigma-Aldrich
(2S,3S,4R)-1-O-(α-D-Galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol, ≥95% (TLC)